

Special Issue

Diagnosis, Monitoring, Prognostication and Treatment in Hepatocellular Carcinoma

Message from the Guest Editor

Since the first tyrosine kinase inhibitor was approved for systemic treatment of advanced hepatocellular carcinoma (HCC) over a decade ago, there has been unprecedented progress in the management and understanding of HCC. Treatment options have been expanded to include immune checkpoint inhibitors, which have now become part of standard of care, and molecular profiling of HCC has identified important drivers that are leading to potentially actionable targets. In addition, newer interventional approaches have been successfully implemented in those with localized disease. Progress is still needed in identifying predictors of treatment response and to determine the role of earlier systemic treatment as adjunct therapy of localized disease. We invite researchers to address one of these topics in the management of HCC from early to late stage disease. I look forward to receiving your contributions.

Guest Editor

Dr. Yoo-Joung Ko

Department of Medicine, Sunnybrook Odette Cancer Centre, Toronto, ON, Canada

Deadline for manuscript submissions

closed (29 March 2024)



Current Oncology

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 4.9
Indexed in PubMed



mdpi.com/si/178547

Current Oncology
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
currentoncology@mdpi.com

[mdpi.com/journal/
currentoncology](https://mdpi.com/journal/currentoncology)





Current Oncology

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 4.9
Indexed in PubMed



[mdpi.com/journal/
currentcol](https://mdpi.com/journal/currentcol)



About the Journal

Message from the Editor-in-Chief

I am honored and enthusiastic to serve as Editor-in-Chief of *Current Oncology*. Since its establishment in 1994, *Current Oncology* has been playing an important role in the advancement of cancer care by disseminating new knowledge in the cancer care continuum. *Current Oncology* is affiliated with several key cancer societies and provides a global platform to share scientific progress in oncology. We strive for high standards and work together to maintain a rigorous and unbiased peer review process to publish high-quality articles. We have an outstanding editorial team which is committed to the success of *Current Oncology*.

Editor-in-Chief

Prof. Dr. Shahid Ahmed

1. College of Medicine, University of Saskatchewan, Saskatoon, SK S7N5E5, Canada
2. Saskatchewan Cancer Agency, Saskatoon Cancer Center, Saskatoon, SK S7N5H5, Canada

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, and other databases.

Journal Rank:

JCR - Q2 (Oncology)